biorasi Blogs

  1. No Shortcuts: Two Pathways To Building A Future For Huntington’s Disease Research 11/16/2021

    One of the tenets of clinical research is that findings often result in more questions than answers. For Huntington’s disease, the journey toward understanding and treatment continues to be a methodical one. Dr. Ole Isacson highlights two pathways to ongoing research for this rare disease.

  2. The Missing Minority: Understanding The Three Main Barriers To Diversity In Today’s Clinical Trials 10/12/2021

    While there are socioeconomic factors contributing to the reasons behind the lack of diversity, the exclusion of minority populations in clinical trials can be a scientifically flawed misstep. By focusing on a single demographic, clinical research findings become limited, and by ignoring other representative populations, "unexpected" side effects may be more commonplace while treatment success levels will vary.

  3. Identifying & Understanding Differentiators In CAR T-Cell Therapy 8/23/2021

    Hematologist Dr. Robert S. Negrin takes a deep dive into identifying and understanding the central differentiators in cell therapy clinical trials.

  4. It Takes Two – The Importance Of Study Partners In Alzheimer’s Disease Clinical Trials 8/23/2021

    Alzheimer’s Disease currently afflicts close to 50 million people worldwide, highlighting the importance of clinical trials for this condition. Alzheimer’s studies are unique in that they require an additional participant to assess the patient’s mental and physical health during the trial. But what are the characteristics of a viable study partner?

  5. What Sets Oncology Clinical Studies Apart From Other Trials? Four Top Differentiators 7/22/2021

    Oncology trials may start out similarly to other therapeutic indications, but they differ radically in relation to early phases of the study, biomarkers, drug characteristics, and competition for patients.  In this article, Dr. Alex Adjei speaks about the top four differentiators in oncology studies that make them unique among other trials.

  6. Managing Alzheimer's Trials In A Diverse Global Environment 7/22/2021

    Diagnostics and treatment for Alzheimer’s Disease vary – both around the world and around the block. In this article, read how recognizing the common disparities for these clinical trials, ranging from standards of care to lack of diversity, brings sponsors and other stakeholders closer to maintaining standardized protocols for Alzheimer’s studies.

  7. Pros And Cons: Defining Site Expertise Across Veteran And Research-Naïve Sites 7/2/2021

    Clinical sites that have a great deal of experience are generally sought after, but can often be busy running other trials. It may be beneficial to consider less experienced sites in order to have more trial options. But of course, there are some necessary considerations when turning to these sites.

  8. Blood Disorder Clinical Trials – Adapting To COVID-19 Challenges 7/2/2021

    The spread of COVID-19 has heightened the potential risk of infection for patients suffering from blood disorders. Hematologist Dr. Robert S. Negrin, a new member of Biorasi’s growing Scientific Advisory Board, weighs in on understanding and adapting to changes to blood disorder trials and treatment during the pandemic.

  9. Spotlight On PNH: The Evolution Of Research And Treatment 6/15/2021

    Paroxysmal nocturnal hemoglobinuria (PNH) is defined as an acquired rare disease triggered by a rare mutation in bone marrow stem cells, with patients experiencing production of irregular blood cells. In terms of clinical studies, PNH’s uniqueness presents a number of operational challenges. In this article, Dr. Mehool Patel discusses innovations in the treatment of PNH, the diverse nature of this rare disease, as well as solutions for PNH clinical trial enrollment and availability.

  10. Determining The "ROI" Of Clinical Trial Rescue Before It's Too Late 5/25/2021

    Have you ever put off broaching a difficult conversation about a faltering clinical trial? Early intervention is a sound solution to putting an at-risk trial back on course.